statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Reneo Pharmaceuticals (RPHM Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on March 28. Analyst Jason Ze...

Sell Rating on Reneo Pharmaceuticals Amid Strategic Uncertainty and Reduced Price Target

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies...

Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

Reneo Pharmaceuticals GAAP EPS of -$2.52...

Reneo Pharmaceuticals GAAP EPS of -$2.52

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
RPHM stock results show that Reneo Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.
The post...

RPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q4 2023

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN...

Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM  Get Free Report) has received an average recommendation of Reduce from the eight research firms that are covering the firm, MarketBeat...

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Receives Consensus Rating of "Reduce" from Brokerages

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM  Get Free Report) has earned an average rating of Reduce from the eight research firms that are presently covering the company...

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Receives $18.14 Consensus Target Price from Analysts

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM  Get Free Report) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totalling...

Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Short Interest Down 15.4% in January

Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company was founded by Michael G. Grey and Niall O'Donnell on September 22, 2014 and is headquartered in San Diego, CA.

Volume	110,683.00
52-Wk High	$9.93
52-Wk Low	$0.9801

Period	Estimated	Reported	Surprise	Result
Q1'24	-$0.44	--	--	N/A
Q4'23	-$0.58	-$0.70	-20.92%	MISSED
Q3'23	-$0.57	-$0.57	0.25%	BEAT
Q2'23	-$0.53	-$0.65	-22.64%	MISSED
Q1'23	-$0.60	-$0.60	0.66%	BEAT

RPHM Reneo Pharmaceuticals Inc

About

Feed

News

Earnings

Fundamentals